These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23625024)

  • 1. Identification of novel small molecule TGF-β antagonists using structure-based drug design.
    Wang H; Sessions RB; Prime SS; Shoemark DK; Allen SJ; Hong W; Narayanan S; Paterson IC
    J Comput Aided Mol Des; 2013 Apr; 27(4):365-72. PubMed ID: 23625024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-β signalling is mediated by two autonomously functioning TβRI:TβRII pairs.
    Huang T; David L; Mendoza V; Yang Y; Villarreal M; De K; Sun L; Fang X; López-Casillas F; Wrana JL; Hinck AP
    EMBO J; 2011 Apr; 30(7):1263-76. PubMed ID: 21423151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ternary complex of transforming growth factor-beta1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily.
    Radaev S; Zou Z; Huang T; Lafer EM; Hinck AP; Sun PD
    J Biol Chem; 2010 May; 285(19):14806-14. PubMed ID: 20207738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer.
    Ajay Kumar TV; Athavan AAS; Loganathan C; Saravanan K; Kabilan S; Parthasarathy V
    Comput Biol Chem; 2018 Oct; 76():232-244. PubMed ID: 30077902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An engineered transforming growth factor β (TGF-β) monomer that functions as a dominant negative to block TGF-β signaling.
    Kim SK; Barron L; Hinck CS; Petrunak EM; Cano KE; Thangirala A; Iskra B; Brothers M; Vonberg M; Leal B; Richter B; Kodali R; Taylor AB; Du S; Barnes CO; Sulea T; Calero G; Hart PJ; Hart MJ; Demeler B; Hinck AP
    J Biol Chem; 2017 Apr; 292(17):7173-7188. PubMed ID: 28228478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based derivation of peptide inhibitors to target TGF-β1 receptor for the suppression of hypertrophic scarring fibroblast activation.
    Hu H; Yang S; Zheng J; Mao G
    Chem Biol Drug Des; 2017 Sep; 90(3):345-351. PubMed ID: 28122173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TbetaR-II discriminates the high- and low-affinity TGF-beta isoforms via two hydrogen-bonded ion pairs.
    Baardsnes J; Hinck CS; Hinck AP; O'Connor-McCourt MD
    Biochemistry; 2009 Mar; 48(10):2146-55. PubMed ID: 19161338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of small molecule inhibitors targeting TGF-β ligand and receptor: Structures, mechanism, preclinical studies and clinical usage.
    Wang H; Chen M; Sang X; You X; Wang Y; Paterson IC; Hong W; Yang X
    Eur J Med Chem; 2020 Apr; 191():112154. PubMed ID: 32092587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2.
    del Re E; Babitt JL; Pirani A; Schneyer AL; Lin HY
    J Biol Chem; 2004 May; 279(21):22765-72. PubMed ID: 14996829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding affinity of transforming growth factor-beta for its type II receptor is determined by the C-terminal region of the molecule.
    Qian SW; Burmester JK; Tsang ML; Weatherbee JA; Hinck AP; Ohlsen DJ; Sporn MB; Roberts AB
    J Biol Chem; 1996 Nov; 271(48):30656-62. PubMed ID: 8940041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPSB1, a Novel Negative Regulator of the Transforming Growth Factor-β Signaling Pathway Targeting the Type II Receptor.
    Liu S; Nheu T; Luwor R; Nicholson SE; Zhu HJ
    J Biol Chem; 2015 Jul; 290(29):17894-17908. PubMed ID: 26032413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor-beta (TGF-beta) binding to the extracellular domain of the type II TGF-beta receptor: receptor capture on a biosensor surface using a new coiled-coil capture system demonstrates that avidity contributes significantly to high affinity binding.
    De Crescenzo G; Pham PL; Durocher Y; O'Connor-McCourt MD
    J Mol Biol; 2003 May; 328(5):1173-83. PubMed ID: 12729750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions.
    Grütter C; Wilkinson T; Turner R; Podichetty S; Finch D; McCourt M; Loning S; Jermutus L; Grütter MG
    Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20251-6. PubMed ID: 19073914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of ALK5 inhibitor via structure-based virtual screening and ADMET prediction.
    Lin A; Cai Z; Hu G; Li Q
    J Recept Signal Transduct Res; 2015; 35(6):559-64. PubMed ID: 26042458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
    Wendt MK; Schiemann WP
    Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGF-β sensitivity is determined by N-linked glycosylation of the type II TGF-β receptor.
    Kim YW; Park J; Lee HJ; Lee SY; Kim SJ
    Biochem J; 2012 Aug; 445(3):403-11. PubMed ID: 22571197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of shear-induced transforming growth factor-β signaling in the endothelium.
    Walshe TE; dela Paz NG; D'Amore PA
    Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2608-17. PubMed ID: 23968981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Small Dibromotyrosine Derivative Purified From Pseudoceratina Sp. Suppresses TGF-β Responsiveness by Inhibiting TGF-β Type I Receptor Serine/Threonine Kinase Activity.
    Chen CL; Kao YC; Yang PH; Sung PJ; Wen ZH; Chen JJ; Huang YB; Chen PY
    J Cell Biochem; 2016 Dec; 117(12):2800-2814. PubMed ID: 27153151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
    Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
    Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor.
    Rotzer D; Roth M; Lutz M; Lindemann D; Sebald W; Knaus P
    EMBO J; 2001 Feb; 20(3):480-90. PubMed ID: 11157754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.